Arkolith/Insider Trading/SYRE/Form 4

Burrows Scott L

Chief Financial OfficerSpyre Therapeutics, Inc. (SYRE) · full profile →Form 4 · filed May 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$892K
Net Open-Market Flow
-$892K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)13K$14.50$181K110K
May 1, 2026Sell(S)13K$71.37$892K98K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)13K—$0382K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001853327-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML